Corticosteroids appear to be effective across the class, including dexamethasone, hydrocortisone and methylprednisolone. The largest trial to date, RECOVERY. examining dexamethasone, reported a huge effect in critically ill patients.
The REMAP-CAP Investigators are soon to release the results of their interleukin 6 receptor antagonist domain, investigating tocilizumab and sarilumab in critically ill patients with COVID-19. We hope to bring you this results presentation at CCR
The multi-platform ATTACC, ACTIV4-A, REMAP-CAP anticoagulation in COVID-19 results are soon to be announced, hopefully at a free live-streamed event hosted by Critical Care Reviews
Disappointingly, all anti-virals tested to date have proven ineffective across multiple trials, including remdesevir, hydroxychloroquine, and lopinovir-ritonavir
